RecruitingNot ApplicableNCT05275738

The Glaucoma Nicotinamide Trial

The Glaucoma Nicotinamide Trial - A Prospective, Randomized, Placebo-controlled, Double-masked Trial


Sponsor

Umeå University

Enrollment

660 participants

Start Date

May 18, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The Glaucoma Nicotinamide Trial (TGNT) is a prospective, randomized, placebo-controlled double-masked clinical trial composed of two cohorts; The Swedish Glaucoma Nicotinamide Trial (SGNT) and the Vitamin B3 In Glaucoma Study (VBIGS). Patients with open-angle glaucoma (OAG) will be randomized to receive either Nicotinamide or placebo through block randomization stratified by glaucoma subtype with a 1:1 allocation.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether nicotinamide (a form of vitamin B3) can slow the progression of glaucoma and protect the optic nerve, compared to standard eye pressure-lowering treatment alone. **You may be eligible if...** - You are an adult (18+) with newly diagnosed and untreated open-angle glaucoma or pseudoexfoliative glaucoma - Your vision is reasonably good (6/12 or better) - You have had at least two reliable visual field tests **You may NOT be eligible if...** - Your glaucoma is already quite advanced (visual field worse than -10 dB in the better eye) - Your eye pressure is 35 mmHg or higher - You already take nicotinamide or niacin supplements - You are allergic to nicotinamide or niacin - You have been diagnosed with cancer in the last 5 years (except certain skin cancers) - You have liver disease or are pregnant/breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTNicotinamide

Study tablets for nicotinamide are produced by Blackmores Ltd.

OTHERPlacebo

Study tablets for placebo are produced by Blackmores Ltd.


Locations(2)

S:t Eriks Eye Hospital

Stockholm, Sweden

Umeå University

Umeå, Sweden

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05275738


Related Trials